SCHEMBL4499142

SCHEMBL4499142

C#Cc1ccc(OC)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACACB O00763 1/20 0.40
PDE4A P27815 1/20 0.39
PDE4B Q07343 1/20 0.39
PDE4C Q08493 1/20 0.39
PDE4D Q08499 1/20 0.39
CA12 O43570 2/20 0.39
CA1 P00915 2/20 0.39
CA2 P00918 2/20 0.39
CA7 P43166 2/20 0.39
CA9 Q16790 2/20 0.39
CA14 Q9ULX7 2/20 0.39
HSP90AA1 P07900 1/20 0.38
HSP90AB1 P08238 1/20 0.38
AR P10275 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
SLC6A4 P31645 5/20 0.36
HTR2A P28223 4/20 0.36
KCNH2 Q12809 3/20 0.36
PGR P06401 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15226652 0.80 ACACB (0.43) ACACBCA12CA1CA2CA7
SCHEMBL966608 0.80 AR (0.57) ARPGRKDM4EMEN1ALDH1A1
SCHEMBL13117493 0.78 ACACB (0.48) ACACBCA12CA1CA2CA7
SCHEMBL987451 0.78 GAA (0.41) ACACBCA12CA1CA2CA7
SCHEMBL29007575 0.78 CA12 (0.40) CA12CA1CA2CA7CA9
SCHEMBL3434561 0.78 CA12 (0.56) ACACBCA12CA1CA2CA7
SCHEMBL17672656 0.77 ALDH1A1 (0.41) CA12CA2ARPGRNFE2L2
SCHEMBL26155371 0.77 ACACB (0.46) ACACBCA12CA1CA2CA7
SCHEMBL29641932 0.76 CYP1A2 (0.42) CA12CA1CA2CA7CA9
SCHEMBL2720566 0.76 CYP1A2 (0.42) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109071468-B Heterocyclic compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2022-09-02 CN disclosed
CN-109071468-A Heterocyclic compound and preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2018-12-21 CN disclosed
EP-2694481-B1 IMIDAZOLE, PYRAZOLE, AND TRIAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER (US) 2015-12-30 EP disclosed
US-8809333-B2 Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents PFIZER INC. (US) 2014-08-19 US disclosed
EP-2694481-A1 IMIDAZOLE, PYRAZOLE, AND TRIAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS Pfizer Inc (US) 2014-02-12 EP disclosed
US-20140038975-A1 Imidazole, Pyrazole, and Triazole Derivatives Useful As Antibacterial Agents BROWN MATTHEW FRANK (US) 2014-02-06 US disclosed
WO-2012137099-A1 IMIDAZOLE, PYRAZOLE, AND TRIAZOLE DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS PFIZER INC. (US) 2012-10-11 WO disclosed
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD (JP) 2009-11-12 US disclosed
EP-1961745-A1 BICYCLIC HETEROCYCLIC COMPOUND ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed
EP-0579908-B1 Pyridyl derivatives, process for their preparation and their use as pesticides BAYER AG (DE) 1997-09-10 EP disclosed
US-5371095-A Fungicides, miticides BAYER AKTIENGESELLSCHAFT (DE) 1994-12-06 US disclosed
EP-0579908-A2 Pyridyl derivatives, process for their preparation and their use as pesticides BAYER AG (DE) 1994-01-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281120-A1 BICYCLIC HETEROCYCLIC COMPOUND CRHR1, NR3C1, CNR1 ACACB 3668/4885PDE4A 2861/4885PDE4B 2915/4885
US-20140038975-A1 Imidazole, Pyrazole, and Triazole Derivatives Useful As Antibacterial Agents AADAC, TPX2, NLRP3 ACACB 2320/4885PDE4A 3153/4885PDE4B 2272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.